The effect of Empagliflozin on left ventricular ejection fraction in non-diabetic patients with acute anterior ST elevation Myocardial infarction treated with primary PCI

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221227056950N1

Enrollment

Registered

2023-01-14

Start date

2023-01-12

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute anterior ST elevation Myocardial infarction treated with primary PCI. ST elevation (STEMI) myocardial infarction of anterior wall

Interventions

Intervention 1: Intervention group:Non-diabetic patients with acute anterior ST elevation Myocardial infarction treated with primary PCI receiving Empagliflozin10 mg once daily for 40 days. Intervent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-Diabetic patients Patients with ejection fraction=40 Patients with anterior ST elevation myocardial infarction Patients undergoing primary percutaneous coronary intervention(PCI) The possibility of patient follow up for electrocardiography Consent to admission to the study

Exclusion criteria

Exclusion criteria: Patients who are candidates for medical therapy after angiography Patients who are candidates for CABG after angiography patients with a history of clinical heart failure patients with a history of Anterior STEMI Patients with a history of PCI on LAD

Design outcomes

Primary

Measure	Time frame
Ejection fraction of left ventricle. Timepoint: Ejection fraction of left ventricle at the beginning of the study and after 40 days of treatment. Method of measurement: Echocardioghraphy.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahar moshfegh

Mashhad University of Medical Sciences

www.moshfeghb70@gmail.com+98 51 3844 4519

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026